新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 投资 » BioCryst Pharmaceuticals获美国联邦政府支持研发埃博拉新药

BioCryst Pharmaceuticals获美国联邦政府支持研发埃博拉新药

来源:生物谷 2015-04-02 12:32

2015年4月2日讯/生物谷BIOON/--BioCryst Pharmaceuticals近日获得美国联邦政府拨款1210万美元,用于支持研发抗埃博拉病毒以及其它疾病的新药,这使得昨日 BioCryst Pharmaceuticals股票的收盘价上涨了5%。

美国卫生部与 BioCryst Pharmaceuticals签订的合同主要是用于继续研发BCX4430,这是一种用于应对RNA病毒感染(比如埃博拉病毒)的新药。

该合同包括1210万美元的基础研发支持,还有2290万美元的额外研发资金,由政府负责。

BCX4430是一种小分子药物,能够阻止埃博拉病毒在体内复制。在非人灵长类动物的试验中,该药物有效地阻止了埃博拉和马尔堡病毒的复制,说明该药物有望成为一种广谱的抗病毒药物。

目前BCX4430的1期临床试验正在进行,联邦政府的自主将有望促进该药品的生产,并且有望推动生产设备的改良,以保证药品生产质量的恒定。(生物谷Bioon.com)

原文 BioCryst wins $12.1m US grant to support Ebola drug

Shares in BioCryst Pharmaceuticals closed up more than 5% yesterday after it won a $12.1 million US federal grant to underpin further development of its antiviral for Ebola and other diseases.

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has awarded the contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses such as Ebola.

This includes a base contract of $12.1 million to support drug manufacturing, as well as $22.9 million in additional development options that can be exercised by the government.

BCX4430 is a small molecule that prevents the Ebola virus from reproducing in the body. In non-human primate studies, the drug was effective against Ebola and Marburg virus, suggesting that it may be useful as a broad spectrum antiviral.

Phase I studies are already underway; the grant will be used to boost manufacturing processes and ramp up production in facilities in the US, “so that thousands of doses can be made with consistent product quality,” the HHS noted.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库